JP2024507937A5 - - Google Patents

Info

Publication number
JP2024507937A5
JP2024507937A5 JP2023551762A JP2023551762A JP2024507937A5 JP 2024507937 A5 JP2024507937 A5 JP 2024507937A5 JP 2023551762 A JP2023551762 A JP 2023551762A JP 2023551762 A JP2023551762 A JP 2023551762A JP 2024507937 A5 JP2024507937 A5 JP 2024507937A5
Authority
JP
Japan
Prior art keywords
sequence
antibody according
multispecific antibody
antigen
binding region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023551762A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024507937A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/054993 external-priority patent/WO2022180271A1/en
Publication of JP2024507937A publication Critical patent/JP2024507937A/ja
Publication of JP2024507937A5 publication Critical patent/JP2024507937A5/ja
Pending legal-status Critical Current

Links

JP2023551762A 2021-02-26 2022-02-28 Cd123及びガンマデルタt細胞受容体に結合する抗体 Pending JP2024507937A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP21159698.6 2021-02-26
EP21159698 2021-02-26
US202163166339P 2021-03-26 2021-03-26
US63/166,339 2021-03-26
US202163274709P 2021-11-02 2021-11-02
US63/274,709 2021-11-02
EP21211114.0 2021-11-29
EP21211114 2021-11-29
PCT/EP2022/054993 WO2022180271A1 (en) 2021-02-26 2022-02-28 Antibodies that bind CD123 and gamma-delta T cell receptors

Publications (2)

Publication Number Publication Date
JP2024507937A JP2024507937A (ja) 2024-02-21
JP2024507937A5 true JP2024507937A5 (cg-RX-API-DMAC10.html) 2025-02-27

Family

ID=80786427

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023551762A Pending JP2024507937A (ja) 2021-02-26 2022-02-28 Cd123及びガンマデルタt細胞受容体に結合する抗体

Country Status (9)

Country Link
US (1) US20240141071A1 (cg-RX-API-DMAC10.html)
EP (1) EP4298125A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024507937A (cg-RX-API-DMAC10.html)
KR (1) KR20230169950A (cg-RX-API-DMAC10.html)
AU (1) AU2022225091A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023017099A2 (cg-RX-API-DMAC10.html)
CA (1) CA3209454A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023009950A (cg-RX-API-DMAC10.html)
WO (1) WO2022180271A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4292610A1 (en) * 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
WO2025012118A2 (en) * 2023-07-07 2025-01-16 LAVA Therapeutics N.V. 5t4 binding agents and methods of use
CN118496370A (zh) * 2024-06-07 2024-08-16 南方医科大学深圳医院 一种靶向alox5纳米抗体及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
FR2879605B1 (fr) 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 1가 항체 및 그의 제조 방법
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
AU2010229705A1 (en) 2009-03-27 2011-10-20 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
WO2012023053A2 (en) 2010-08-16 2012-02-23 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
DK2924052T3 (da) 2012-11-21 2019-09-30 Pharmabcine Inc Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme
US10501540B2 (en) 2014-04-10 2019-12-10 Lava Therapeutics B.V. Immunoglobulins binding human Vγ9 Vδ2 T cell receptors
TW202010757A (zh) * 2018-04-11 2020-03-16 美商英伊布里克斯公司 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
JP7457007B2 (ja) * 2018-09-19 2024-03-27 ラヴァ・セラピューティクス・エヌ・ヴイ 二重作用CD1d免疫グロブリン
CN114040926B (zh) * 2019-05-04 2025-07-29 印希比生物科学有限公司 结合cd123的多肽及其用途
JP7686571B2 (ja) 2019-05-08 2025-06-02 ヤンセン バイオテツク,インコーポレーテツド T細胞媒介性免疫を調節するための材料及び方法

Similar Documents

Publication Publication Date Title
JP2023139070A5 (cg-RX-API-DMAC10.html)
JP2024501403A5 (cg-RX-API-DMAC10.html)
JP2020010699A5 (cg-RX-API-DMAC10.html)
JP2021508469A5 (cg-RX-API-DMAC10.html)
JP2021510521A5 (cg-RX-API-DMAC10.html)
HRP20191174T1 (hr) Bispecifične molekule vezane na antigen koji aktivira t stanicu
JP2019533441A5 (cg-RX-API-DMAC10.html)
JP2019501883A5 (cg-RX-API-DMAC10.html)
JP2022519082A5 (cg-RX-API-DMAC10.html)
JP2020504723A5 (cg-RX-API-DMAC10.html)
JP2020511947A5 (cg-RX-API-DMAC10.html)
RU2019134338A (ru) Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15
JP2019502712A5 (cg-RX-API-DMAC10.html)
RU2018143439A (ru) Антигенсвязывающие молекулы, содержащие тримерный лиганд семейства tnf и pd1-связывающий фрагмент
JP2018519263A5 (cg-RX-API-DMAC10.html)
WO2017198741A1 (en) Anti pd-1 and anti-lag3 antibodies for cancer treatment
JP2023532129A5 (cg-RX-API-DMAC10.html)
CA3091140A1 (en) Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer
JP2018505177A5 (cg-RX-API-DMAC10.html)
IL292780A (en) A new 4-1bbl trimer containing antigen-binding molecules
JP2017504314A5 (cg-RX-API-DMAC10.html)
JP2020502233A5 (cg-RX-API-DMAC10.html)
JP2017534646A5 (cg-RX-API-DMAC10.html)
JP2024541680A5 (cg-RX-API-DMAC10.html)
JP2024537779A5 (cg-RX-API-DMAC10.html)